Rathbones Group PLC Raises Stock Holdings in ASP Isotopes Inc. $ASPI

Rathbones Group PLC grew its position in shares of ASP Isotopes Inc. (NASDAQ:ASPI) by 68.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 399,599 shares of the company’s stock after buying an additional 162,535 shares during the period. Rathbones Group PLC’s holdings in ASP Isotopes were worth $2,138,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Quantbot Technologies LP bought a new position in ASP Isotopes during the 3rd quarter worth approximately $34,000. BNP Paribas Financial Markets lifted its holdings in ASP Isotopes by 84.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company’s stock worth $41,000 after buying an additional 2,548 shares during the last quarter. IFP Advisors Inc bought a new position in ASP Isotopes during the 4th quarter worth approximately $48,000. Pictet Asset Management Holding SA bought a new position in ASP Isotopes during the 4th quarter worth approximately $61,000. Finally, Close Asset Management Ltd bought a new position in ASP Isotopes during the 3rd quarter worth approximately $72,000. Institutional investors own 16.80% of the company’s stock.

ASP Isotopes Trading Up 7.4%

NASDAQ:ASPI opened at $5.55 on Friday. The company has a quick ratio of 12.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.69. The business’s 50 day moving average is $5.06 and its two-hundred day moving average is $5.95. ASP Isotopes Inc. has a 52 week low of $3.92 and a 52 week high of $14.49. The company has a market cap of $698.75 million, a PE ratio of -2.67 and a beta of 3.26.

ASP Isotopes (NASDAQ:ASPI) last announced its quarterly earnings results on Wednesday, May 20th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.06. The business had revenue of $8.36 million for the quarter, compared to analysts’ expectations of $3.68 million. ASP Isotopes had a negative return on equity of 112.46% and a negative net margin of 644.40%.

Analyst Ratings Changes

ASPI has been the topic of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ASP Isotopes in a report on Friday, March 27th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $11.00 target price on shares of ASP Isotopes in a report on Tuesday, April 14th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $13.00.

Insider Transactions at ASP Isotopes

In other news, CFO Heather Kiessling sold 23,124 shares of the stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $5.48, for a total transaction of $126,719.52. Following the sale, the chief financial officer directly owned 709,376 shares in the company, valued at approximately $3,887,380.48. This represents a 3.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Duncan Moore sold 11,642 shares of the stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $5.21, for a total value of $60,654.82. Following the sale, the director owned 1,044,928 shares in the company, valued at $5,444,074.88. The trade was a 1.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 90,704 shares of company stock worth $463,252. 14.40% of the stock is currently owned by company insiders.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.